[{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"Granulocyte colony stimulating factor receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Fresenius Kabi AG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fresenius Kabi AG \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"Granulocyte colony stimulating factor receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Fresenius Kabi AG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fresenius Kabi AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Damoctocog Alfa Pegol","moa":"Coagulation factor VIII","graph1":"Hematology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Inapplicable"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          December 07, 2021

                          Lead Product(s) : Damoctocog Alfa Pegol

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Details : U.S. Food and Drug Administration (FDA) has accepted for review the company’s Biologics License Application (BLA) for MSB11455, a biosimilar candidate of Neulasta®* (pegfilgrastim).

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          May 27, 2020

                          Lead Product(s) : Pegfilgrastim

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Details : Fresenius Kabi’s MAA submission for pegfilgrastim biosimilar candidate includes analytical, pharmacokinetic, pharmacodynamic, safety and immunogenicity data.

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          May 22, 2020

                          Lead Product(s) : Pegfilgrastim

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 01, 2018

                          Lead Product(s) : Molidustat

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 01, 2018

                          Lead Product(s) : Molidustat

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 22, 2017

                          Lead Product(s) : Molidustat

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 22, 2017

                          Lead Product(s) : Molidustat

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 22, 2017

                          Lead Product(s) : Molidustat

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          November 17, 2017

                          Lead Product(s) : Idarucizumab

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 23, 2016

                          Lead Product(s) : Dabigatran Etexilate Mesylate

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank